COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Routes of Immunization and Flu Immune Responses (FLUWAY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01707602
Recruitment Status : Completed
First Posted : October 16, 2012
Last Update Posted : August 5, 2013
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The project aims to evaluate the impact of skin routes of immunization (transcutaneous and intradermal vs intramuscular) on cellular and humoral responses to seasonal influenza vaccination in adults (18-45 years old).

Condition or disease Intervention/treatment Phase
Influenza Biological: INTANZA® 15 Biological: Vaxigrip® Biological: INTANZA® 15 T Phase 1 Phase 2

Detailed Description:

New approaches addressing intradermal (ID) and transcutaneous (TC) routes of immunization have been developed over the past few years and have brought novel insight in quality and efficacy of the immune response. Indeed, compared to the muscular tissue widely used for vaccination, the skin is particularly rich in antigen presenting cells. Our recent works show that penetration of vaccine compounds into the hair follicular ducts surrounded by Langerhans cells induces potent cellular immunity in contrast to the intra-muscular immunization. Our results also suggest that differential targeting of epidermal Langerhans cells (by TC route) or dermal dendritic cells (by ID route) could modulate the intensity and quality of the immune response to vaccine.

The aim of this study is to evaluate the immune response to a seasonal influenza vaccine when administrated byTC (hair follicular targeting needle-free method), ID (micro-needle injection) and IM (conventional intramuscular injection) routes of immunization. Along with our previous pre-clinical and clinical studies, here we hypothesize that differential targeting of epidermis or dermis antigen-presenting cells will have a differential impact on the cellular and humoral immune responses to Influenza vaccine.


We will conduct a phase I/II clinical trials on 60 healthy volunteers to compare TC and ID routes of immunization to the conventional intramuscular (IM) vaccination. The impact of these routes on cellular and humoral immune responses to seasonal influenza vaccine will be assessed at baseline, day 21 (effector phase) and month 5 (memory phase) after vaccination.


Using the seasonal Influenza vaccine as an example of conventional vaccine, this study will evaluate and compare the efficacy ofTC, ID and IMroutes of immunization to induce cellular responses at day 21 and memory responses at month 5 phases. The generation and maintenance of Flu specific and neutralizing antibodies will be measured by Haemagglutination Inhibition and microneutralization assays.Moreover, safety and tolerance to each vaccination methods will be evaluated as well as inflammation and innate immune response induced at day 1 after vaccination.

Addressing innovative skin routes of immunization, this study represents an essential step to move forward in the development of new vaccination strategies. These results will have an important impact on the amelioration of vaccine efficacy and less invasive method of immunization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Impact of Immunization Routes on the Immune Response to Influenza Vaccine
Study Start Date : October 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: Arm A
Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
Biological: INTANZA® 15 T
transcutaneous vaccination

Active Comparator: Arm B
Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
Biological: INTANZA® 15
intradermal vaccination

Active Comparator: Arm C
Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
Biological: Vaxigrip®
Intramuscular vaccination

Primary Outcome Measures :
  1. CD8 T cell responses [ Time Frame: 21 days ]
    CD8 T cell responses against the specific vaccine strain will be measured at baseline and day 21 after vaccination by flow cytometry. Secretion of cytokines measured by intracellular staining will be compared between TC, ID and IM routes of vaccination.

Secondary Outcome Measures :
  1. Safety [ Time Frame: 5 months ]
    Safety will be assessed at each visit by recording clinical local and systemic tolerance including reporting of adverse events. Frequency and severity of local and systemic adverse events following vaccination will be compared between TC, ID and IM vaccination groups.

  2. Haemagglutination Inhibition [ Time Frame: 5 months ]
    Haemagglutination Inhibition and microneutralization assays will be performed at day0, day 21 and month 5 after vaccination to define the humoral response against a vaccine-homologous virus that meets or exceeds the EMEA (CHMP) guidance targets for influenza vaccine seroconversion rate (SCR), seroprotection rate (SPR), and geometric mean fold rise (GMFR).

  3. CD4 T cell responses [ Time Frame: 21 days ]
    CD4 T cell responses against the specific vaccine strain will be measured at baseline and day 21 by intracellular staining and flow cytometry. Effector CD4 T cell responses will be compared between TC, ID and IM vaccination groups.

  4. Memory CD8 and CD4 T cell responses [ Time Frame: 5 months ]
    Memory CD8 and CD4 T cell responses against the specific vaccine strain will be assessed by flow cytometry 5 month after vaccination by TC, ID and IM routes.

  5. Inflammation [ Time Frame: 1 day ]
    Inflammation and systemic innate immune response will be assessed on day 1 after vaccination (compared with the basal inflammatory status) by studying the transcriptional profile of blood cells (microarrays) and inflammatory cytokines dosage in the serum.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers, age between 18 and 45 years,
  • BMI between 21 - 26,
  • Phototype I to IV,
  • Subjects able to receive vaccine administration by any of the three administration routes,
  • Signature of the written informed consent,
  • Affiliated to a health social security system,

Exclusion Criteria:

  • Known pregnancy or positive urine pregnancy test for women of child-bearing age,
  • Known infection with HIV or/and HCV or/and HBV (AgHBs+),
  • Known or suspected immune dysfunction that is caused by a medical condition, or any other Cause,
  • Use, within the past 3 months, of any topical and systemic treatment that would interfere with assessment and/or investigational treatment (anti-inflammatory drugs, immunosuppressors or any immune modulator agent),
  • Use of any topical treatment on the injection site within the last four weeks,
  • Excessive terminal hair growth on the two investigational skin areas used for the transcutaneous mode of vaccination,
  • Phototype V-VI,
  • Any allergy or hypersensibility to one of the components of the Investigational Product,
  • Medical history of allergy or hypersensitization to any ingredient of colorant used in the transcutaneous mode of administration,
  • Administration of a live vaccine(≤ 28 days) or inactivated (≤ 14 days) or planned vaccination within 3months of inclusion (D0),
  • Medical history of skin cancer,
  • Any acute skin affection which may interfere with the trial assessment on the injection site,
  • Any acute or chronic infectious which may interfere with the trial assessment four weeks prior to enrolment,
  • Prevision of UV sessions or sun exposure 6 weeks prior to the study or during the study period,
  • Febrile illness(at least 37.5°Cmeasuredorally), any acute infectious event within one week prior to enrolment,
  • Flu confirmed by the presence of fever≥38.5°Cassociated with respiratory symptoms
  • History of GuillainBarre syndrome or brachial neuritis following a previous vaccination.
  • Participation in an other biomedical research during the study period or period of exclusion when inclusion
  • Subject being in the exclusion period of a previous clinical trial,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01707602

Layout table for location information
GH Cochin - Broca - Hôtel-Dieu CIC BT505
PARIS Cedex 14, France, 75679
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France
Layout table for investigator information
Principal Investigator: Odile LAUNAY, M.D. Ph. D Assistance Publique - Hôpitaux de Paris

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT01707602    
Other Study ID Numbers: P120201
2012-001967-55 ( EudraCT Number )
First Posted: October 16, 2012    Key Record Dates
Last Update Posted: August 5, 2013
Last Verified: July 2013
Keywords provided by Assistance Publique - Hôpitaux de Paris:
routes of vaccination
T cell responses
humoral responses
clinical trial
Novel application of influenza vaccine
Transcutaneous vaccination(hair follicular targeting)
Intradermal vaccination(micro-needle)
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases